<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577716</url>
  </required_header>
  <id_info>
    <org_study_id>AC20136</org_study_id>
    <nct_id>NCT04577716</nct_id>
  </id_info>
  <brief_title>Predicting Endoleaks Following Endovascular Aortic Aneurysm Repair Using 18F-Sodium Fluoride</brief_title>
  <acronym>PET-EVAR</acronym>
  <official_title>The PET-EVAR Study - Predicting Endoleaks Following Endovascular Aortic Aneurysm Repair Using 18F-Sodium Fluoride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Lanarkshire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to describe Sodium Fluoride uptake (using Positron Emission&#xD;
      Tomography-Computed Tomography - PET-CT) following Endovascular Aneurysm Repair (EVAR) and to&#xD;
      determine whether Sodium Fluoride PET-CT can predict the development of endoleaks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abdominal aortic aneurysms are a leading cause of death in the United Kingdom. Surveillance&#xD;
      programmes and pre-emptive surgical repair are lifesaving. Traditional open surgical repair&#xD;
      is associated with major perioperative morbidity and mortality and there has been a move&#xD;
      towards minimally invasive Endovascular Aneurysm Repair (EVAR), which reduces these early&#xD;
      risks. However, the cost effectiveness and long-term clinical effectiveness of EVAR is&#xD;
      undermined by concerns of durability due to the development of endoleaks and late aneurysm&#xD;
      rupture secondary to progression of native aortic aneurysm disease and stent graft failure.&#xD;
      It has previously been demonstrated that 18F-Sodium Fluoride Positron Emission Tomography can&#xD;
      predict progression of aneurysm disease and is associated with greater rates of abdominal&#xD;
      aortic aneurysm expansion and the future risk of rupture or surgical repair.&#xD;
&#xD;
      The investigators here wish to examine whether 18F-Sodium Fluoride on Positron Emission&#xD;
      Tomography uptake (i) is increased in patients with endoleaks or related complications, (ii)&#xD;
      can prospectively predict the likelihood of developing endoleaks in patients undergoing EVAR,&#xD;
      and (ii) is a feasible approach to select patients for EVAR with a reduced future risk of&#xD;
      stent graft failure and re-intervention. The investigators believe that there is a compelling&#xD;
      scientific rationale for this approach with major translational potential to better select&#xD;
      subgroups of patients for EVAR and ultimately improve their outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microcalcification activity in stented and aneurysmal aorta</measure>
    <time_frame>12 months</time_frame>
    <description>Will be measured as 18F Sodium Fluoride binding in the aorta. Uptake will be quantified in Standardised Uptake Values and as a tissue to background ratios.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pattern of microcalcification activity in the stented aorta</measure>
    <time_frame>12 months</time_frame>
    <description>Microcalcification activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of microcalcification activity in the stented aorta</measure>
    <time_frame>12 months</time_frame>
    <description>Microcalcification activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoleaks</measure>
    <time_frame>12 months</time_frame>
    <description>Computed tomography and ultrasound endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent graft migration</measure>
    <time_frame>12 months</time_frame>
    <description>Computed tomography and ultrasound endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm sac diameter</measure>
    <time_frame>12 months</time_frame>
    <description>Computed tomography and ultrasound endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck diameter and neck angulation</measure>
    <time_frame>12 months</time_frame>
    <description>Computed tomography and ultrasound endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometry: tortuosity, curvature, torsion</measure>
    <time_frame>12 months</time_frame>
    <description>Computed tomography and ultrasound endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm-related mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical endpoints</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Co-localisation of 18F-Sodium Fluoride with histological changes in aortic tissue</measure>
    <time_frame>12-36 months</time_frame>
    <description>Uptake of 18F-Sodium Fluoride will be identified on PET-CT scans that are acquired as part of the study visit. This will be compared with histological changes in aortic specimens obtained if participant undergoes an open aortic procedure during the study period.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <condition>Endoleak</condition>
  <condition>Stent-Graft Endoleak</condition>
  <arm_group>
    <arm_group_label>Endoleak Group</arm_group_label>
    <description>Participants with a previous Endovascular Aneurysm Repair (EVAR) who have developed an endoleak</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Endoleak Group</arm_group_label>
    <description>Participants with a previous Endovascular Aneurysm Repair (EVAR) who have not developed an endoleak</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-EVAR Group</arm_group_label>
    <description>Participants who have an abdominal aortic aneurysm and who are undergoing an Endovascular Aneurysm Repair as standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F Sodium Fluoride Positron Emission Tomography / Computed Tomography</intervention_name>
    <description>PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan</description>
    <arm_group_label>Endoleak Group</arm_group_label>
    <arm_group_label>No Endoleak Group</arm_group_label>
    <arm_group_label>Pre-EVAR Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT Aortic Angiogram</intervention_name>
    <description>CT scan to assess aortic morphology and contextualise PET scan</description>
    <arm_group_label>Endoleak Group</arm_group_label>
    <arm_group_label>No Endoleak Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>12-month CT Aortic Angiogram</intervention_name>
    <description>CT scan to assess aortic morphology and the stent graft</description>
    <arm_group_label>Pre-EVAR Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>24-month review</intervention_name>
    <description>This will consist of a telephone consultation with the study participant and review of electronic clinical records</description>
    <arm_group_label>Pre-EVAR Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Aortic tissue specimens obtained from individuals undergoing open surgical repair will be&#xD;
      studied histologically, using autoradiography and micro-PET/CT.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of individuals with an abdominal aortic aneurysm (AAA).&#xD;
        The first part of the study (Study 1 - Case Control Study) will recruit patients with&#xD;
        existing EVAR in to two groups: patients that have an endoleak or related complication&#xD;
        (endoleak group, n = 22) and those that have remained complication-free (no endoleak group,&#xD;
        n = 22). We will also prospectively recruit patients who are yet to receive EVAR or&#xD;
        fenestrated EVAR (pre-EVAR group, n = 100) for the (Study 2 - Cohort Study).&#xD;
&#xD;
        There will be four patient identification centres from which patients will be recruited:&#xD;
        NHS Lothian, NHS Lanarkshire, NHS Greater Glasgow and Clyde, and NHS Tayside.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of AAA as defined by the European Society of Vascular Surgery guidelines&#xD;
             on the management of aorto-iliac artery aneurysms, and having undergone endovascular&#xD;
             repair within the recommended Instructions For Use (IFU) by the manufacturer.&#xD;
             ['Endoleak' and 'No Endoleak groups only]&#xD;
&#xD;
          -  Complication will be defined as any type of endoleak or stent graft migration&#xD;
             ['Endoleak' group only].&#xD;
&#xD;
          -  A diagnosis of AAA requiring endovascular repair OR a diagnosis of juxtarenal AAA&#xD;
             requiring fenestrated endovascular aneurysm repair as defined by the European Society&#xD;
             of Vascular surgery guidelines on the management of aorto-iliac artery aneurysms and&#xD;
             planned EVAR or fenestrated EVAR surgery. ['pre-EVAR' group only]&#xD;
&#xD;
          -  Minimum age: 50 years. No maximum age.&#xD;
&#xD;
          -  Retain capacity for informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The inability of patients to undergo PET/CT scanning&#xD;
&#xD;
          -  Chronic kidney disease (eGFR ≤ 30 mL/min/1.73 m2)&#xD;
&#xD;
          -  Major or untreated cancer&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Allergy or contra-indication to iodinated contrast&#xD;
&#xD;
          -  Inability or unwillingness to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Debono</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel Debono</last_name>
    <phone>01312426515</phone>
    <email>samuel.debono@ed.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <zip>DD2 1SG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Mr Suttie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hairmyres</name>
      <address>
        <city>East Kilbride</city>
        <zip>G75 8RG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Mr Vesey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Mr Tambyraja</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Professor Brittenden</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EVAR</keyword>
  <keyword>Endoleak</keyword>
  <keyword>18F-Sodium Fluoride</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
    <mesh_term>Endoleak</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Listerine</mesh_term>
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are no plans for individual participant data sharing.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

